About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acurx Pharmaceuticals, Inc. - Common Stock (NQ:ACXP)

1.065 -0.025 (-2.29%)
Delayed Quote Updated: 3:29 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acurx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
AcurX Pharmaceuticals’ C. Difficile Drug Candidate Could Fetch $800 Million On A Peer Comparison Basis (NASDAQ: ACXP)
Via AB Newswire
VIDEO Report: Acurx Pharmaceuticals’ Ibezapolstat In Focus As A Best-In-Class Treatment For Gram Positive Infections (NASDAQ: ACXP)
Via AB Newswire
CEO In Focus: Acurx Pharma CEO Confident His Company’s Phase 2b Ibezapolstat Trial Can Lead To A Front-Line Treatment For C. difficile (NASDAQ: ACXP)
Via AB Newswire
News headline image
CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts
New York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing... 
Via Newsfile
Topics Death Derivatives Initial Public Offering
News headline image
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Acurx Pharmaceutical’s Reaches Another Milestone With Russell Microcap Inclusion; Shares Extend August Gains (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceutical’s Is Disruptive To The Antibiotics Landscape- That’s Great News For Patients With Gram-Positive Infections (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Plan To Change The Antibiotics Landscape Is Simple- Make Better Drugs That Target Gram-Positive Infections
Via AB Newswire
Acurx Pharmaceutical’s On Pace To Change The Antibiotics Landscape; Trial Data Shows 100% Sustained Clinical Cure In Treating Gram-Positive Infection CDI
Via AB Newswire
Drug Makers Overseas Are Gaining A Competitive Advantage In The Antibiotics R&D Market; Acurx Pharmaceuticals Ibezapolstat Program Is Helping Level The Field (NASDAQ: ACXP)
Via AB Newswire
News headline image
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Gram Positive Bacterial Infections Can Be Fatal; Acurx Pharmaceuticals Is One Of The Few Working To Change The Treatment Landscape (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Leverages IPO Capital To Develop Most Significant Advance To Antibiotics In More Than 40 Years (NASDAQ: ACXP)
Via AB Newswire
Topics Initial Public Offering
News headline image
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs ↗
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Acurx Pharmaceuticals On Pace To Deliver The Most Important Upgrade To Antibiotics Since The 1980s (NASDAQ: ACXP)
Via AB Newswire
Topics Initial Public Offering
Post-IPO Acurx Pharmaceuticals Expects To Deliver The First Meaningful Change To Antibiotics Market Since 1980s (NASDAQ: ACXP)
Via AB Newswire
Topics Initial Public Offering
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
Before 10 a.m. ET on Friday, 43 companies set new 52-week lows. Points of Interest: Autohome (NYSE:ATHM) was the largest firm by market cap to set a new 52-week low... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Acurx Pharmaceuticals Shares 15% Higher Post-IPO; On Track To Bring A New Class Of Effective Antibiotics To Market (NASDAQ: ACXP)
Via AB Newswire
Topics Initial Public Offering
News headline image
60 Biggest Movers From Yesterday ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
News headline image
44 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook ↗
Following the market opening Monday, the Dow traded down 0.30% to 34,329.01 while the NASDAQ rose 0.60% to 14,446.74. The S&P also rose, gaining 0.04% to 4,282.58. The U.S.... 
Via Benzinga
Topics Stocks
Acurx Pharmaceuticals Shares Surge 31% Following Its Debut Public Offering; Low Share Count And $15 Million Presents A Compelling Investment Opportunity
Via AB Newswire
Topics Initial Public Offering
News headline image
24 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
News headline image
55 Biggest Movers From Friday ↗
Gainers IKONICS Corporation (NASDAQ: IKNX) shares surged 64.3% to close at $18.56 on Friday after the company reported a merger deal with TeraWulf. Alpha Teknova, Inc. (NASDAQ:... 
Via Benzinga
News headline image
Software Startup Sprinklr Falls In Market Debut, More IPO News ↗
Shares of Sprinklr fell almost 9% in their market debut on Wednesday, valuing the startup at $3.7B. The software company counts Microsoft and Verizon as customers. Didi and Krispy Kreme are among... 
Via Talk Markets
Topics Initial Public Offering
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.